AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT01207089
- Locations
- 🇬🇧
Research Site, London, United Kingdom
An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT01206231
- Locations
- 🇷🇸
Research Site, Uzice, Serbia
Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT01205867
- Locations
- 🇩🇰
Research Site, Copenhagen, Denmark
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: AZD8683, 50 mcgDrug: PlaceboDrug: AZD8683, 200 mcg
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01205269
- Locations
- 🇵🇱
Research Site, Łódź, Poland
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Phase 4
Completed
- Conditions
- Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1060
- Registration Number
- NCT01203917
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Placebo (Saxagliptin)Drug: Placebo (Metformin)
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT01204775
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 301
- Registration Number
- NCT01203904
- Locations
- 🇯🇵
Research Site, Yamaguchi, Japan
Seroquel XR in the Long Term Treatment of Schizophrenia
Completed
- Conditions
- Relapse in Schizophrenia
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1606
- Registration Number
- NCT01202617
- Locations
- 🇭🇺
Research Site, Zalegerszeg, Hungary
A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT01203124
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients
Phase 1
Completed
- Conditions
- FGFR Inhibition, Pharmacokinetics, BiomarkersER+ Breast Cancer
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 127
- Registration Number
- NCT01202591
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom